Chelsea Therapeutics, Inc. Achieves Target Enrollment in Phase II Trial of Droxidopa in Fibromyalgia

CHARLOTTE, N.C., Aug. 8, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has successfully reached its target enrollment of 120 patients in its Phase II trial of droxidopa for the treatment of fibromyalgia. Top-line results of the trial are expected by the end of the year.
MORE ON THIS TOPIC